CA2376630A1 - Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt - Google Patents

Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt Download PDF

Info

Publication number
CA2376630A1
CA2376630A1 CA002376630A CA2376630A CA2376630A1 CA 2376630 A1 CA2376630 A1 CA 2376630A1 CA 002376630 A CA002376630 A CA 002376630A CA 2376630 A CA2376630 A CA 2376630A CA 2376630 A1 CA2376630 A1 CA 2376630A1
Authority
CA
Canada
Prior art keywords
vegf
akt
nucleic acid
protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002376630A
Other languages
English (en)
French (fr)
Inventor
Kun Guo
Yuri Ivashchenko
Kenneth Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gencell Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2376630A1 publication Critical patent/CA2376630A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002376630A 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt Abandoned CA2376630A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13872499P 1999-06-11 1999-06-11
US60/138,724 1999-06-11
GB9926058 1999-11-03
GB9926058.0 1999-11-03
PCT/US2000/015098 WO2000077190A2 (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Publications (1)

Publication Number Publication Date
CA2376630A1 true CA2376630A1 (en) 2000-12-21

Family

ID=26316052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002376630A Abandoned CA2376630A1 (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Country Status (17)

Country Link
EP (1) EP1187911A2 (zh)
JP (1) JP2003530818A (zh)
KR (1) KR20020012270A (zh)
CN (1) CN1360629A (zh)
AU (1) AU773450B2 (zh)
BR (1) BR0011503A (zh)
CA (1) CA2376630A1 (zh)
CZ (1) CZ20014444A3 (zh)
HK (1) HK1041500A1 (zh)
HU (1) HUP0201663A3 (zh)
IL (1) IL146730A0 (zh)
MX (1) MXPA01012748A (zh)
NO (1) NO20016025L (zh)
NZ (1) NZ516054A (zh)
PL (1) PL352859A1 (zh)
SI (1) SI20978A (zh)
WO (1) WO2000077190A2 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
DE60039677D1 (de) * 1999-03-19 2008-09-11 Aventis Pharma Inc Akt-3 nukleinsäure, polypeptide und deren verwendung
CN100357433C (zh) * 1999-04-16 2007-12-26 耶鲁大学 可用于基因治疗和治疗性筛选的eNOS突变
US6187586B1 (en) * 1999-12-29 2001-02-13 Isis Pharmaceuticals, Inc. Antisense modulation of AKT-3 expression
US20010038842A1 (en) * 2000-03-02 2001-11-08 Marc Achen Methods for treating various cancers expressing vascular endothelial growth factor D, for screening for a neoplastic disease and for maintaining vascularization of tissue
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039677D1 (de) * 1999-03-19 2008-09-11 Aventis Pharma Inc Akt-3 nukleinsäure, polypeptide und deren verwendung

Also Published As

Publication number Publication date
KR20020012270A (ko) 2002-02-15
HUP0201663A3 (en) 2005-01-28
JP2003530818A (ja) 2003-10-21
CN1360629A (zh) 2002-07-24
PL352859A1 (en) 2003-09-08
IL146730A0 (en) 2002-07-25
BR0011503A (pt) 2002-03-05
WO2000077190A2 (en) 2000-12-21
AU5175800A (en) 2001-01-02
EP1187911A2 (en) 2002-03-20
NZ516054A (en) 2004-04-30
HK1041500A1 (zh) 2002-07-12
CZ20014444A3 (cs) 2002-05-15
HUP0201663A2 (en) 2002-08-28
AU773450B2 (en) 2004-05-27
SI20978A (sl) 2003-02-28
NO20016025D0 (no) 2001-12-10
WO2000077190A3 (en) 2001-04-12
NO20016025L (no) 2002-02-08
MXPA01012748A (es) 2002-07-02

Similar Documents

Publication Publication Date Title
US7662628B2 (en) Human Akt3 nucleic acid and uses thereof
IL190270A (en) Use of 3AKT nucleic acids for the preparation of a drug for the treatment of cell death, treatment of myocardial infarction or injury due to blockage in the blood supply
AU773450B2 (en) Induction of vascular endothelial growth factor (VEGF) by the serine/threonine protein kinase AKT
AU2005203749A1 (en) Variants of Traf2 which act as an inhibitor of TNF-ALPHA (TNF alpha) signaling pathway
JP2002515223A (ja) Ｔａｏプロテインキナーゼおよびその使用方法
US7005285B1 (en) Human p21-activated kinase 5 polypeptide
WO1999002701A1 (en) Pak kinase genes and polypeptides and methods of use thereof
MXPA01009431A (en) Akt nucleic acids, polypeptides, and uses thereof
US7332593B2 (en) Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNFα) signaling pathway

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued